Literature DB >> 10390421

Antigen-induced airway inflammation in atopic subjects generates dysfunction of pulmonary surfactant.

N N Jarjour1, G Enhorning.   

Abstract

If pulmonary surfactant develops a dysfunction, its ability to maintain patency of narrow conducting airways diminishes, which is likely to cause an increased airway resistance. We hypothesized that antigen challenge will cause inflammation in the conducting airways and that this will cause a surfactant dysfunction. Twenty atopic patients underwent bronchoalveolar lavage (BAL) 5 min and 48 h after challenge with antigen in one segment and with saline solution in another. BAL fluid (BALF) cell count, differential, and proteins were determined. Surfactant function was studied with a capillary surfactometer (CS), an instrument specifically designed to evaluate surfactant's ability to maintain patency. Eosinophils increased 80-fold 48 h after antigen challenge and total protein increased from 84 to 241 micrograms/ml (median values). BALF surfactant lost part of its ability to maintain openness of the capillary, from 68.8% to 14.0% (p < 0.05). Protein concentration negatively correlated with percent openness (r = -0.62, p = 0.005). We conclude that the antigen challenge resulted in an inflammatory reaction that caused pulmonary surfactant to lose some of its ability to maintain airway patency and speculate that surfactant dysfunction is probably an important factor contributing to increased airway obstruction in allergen-induced exacerbation of asthma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10390421     DOI: 10.1164/ajrccm.160.1.9806155

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  11 in total

Review 1.  Coagulation-dependent mechanisms and asthma.

Authors:  Michael A Matthay; John A Clements
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

Review 2.  Therapeutic use of surfactant components in allergic asthma.

Authors:  Veit J Erpenbeck; Norbert Krug; Jens M Hohlfeld
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-10-15       Impact factor: 3.000

Review 3.  Mechanisms of airway hyper-responsiveness in asthma: the past, present and yet to come.

Authors:  D G Chapman; C G Irvin
Journal:  Clin Exp Allergy       Date:  2015-04       Impact factor: 5.018

4.  Plasminogen-stimulated airway smooth muscle cell proliferation is mediated by urokinase and annexin A2, involving plasmin-activated cell signalling.

Authors:  A G Stewart; Y C Xia; T Harris; S Royce; J A Hamilton; M Schuliga
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

5.  Secretory phospholipase A2-mediated depletion of phosphatidylglycerol in early acute respiratory distress syndrome.

Authors:  Michael C Seeds; Bonnie L Grier; Bruce N Suckling; Anca M Safta; David L Long; B Moseley Waite; Peter E Morris; R Duncan Hite
Journal:  Am J Med Sci       Date:  2012-06       Impact factor: 2.378

Review 6.  Eosinophil-associated lung diseases. A cry for surfactant proteins A and D help?

Authors:  Julie G Ledford; Kenneth J Addison; Matthew W Foster; Loretta G Que
Journal:  Am J Respir Cell Mol Biol       Date:  2014-11       Impact factor: 6.914

Review 7.  Physiologic dysfunction of the asthmatic lung: what's going on down there, anyway?

Authors:  Charles G Irvin; Jason H T Bates
Journal:  Proc Am Thorac Soc       Date:  2009-05-01

8.  Extravascular fibrin, plasminogen activator, plasminogen activator inhibitors, and airway hyperresponsiveness.

Authors:  Scott S Wagers; Ryan J Norton; Lisa M Rinaldi; Jason H T Bates; Burton E Sobel; Charles G Irvin
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

9.  Site of allergic airway narrowing and the influence of exogenous surfactant in the Brown Norway rat.

Authors:  Sana Siddiqui; Kimitake Tsuchiya; Paul-André Risse; Sharon R Bullimore; Andrea Benedetti; James G Martin
Journal:  PLoS One       Date:  2012-01-19       Impact factor: 3.240

10.  Decreased biosynthesis of lung surfactant constituent phosphatidylcholine due to inhibition of choline transporter by gefitinib in lung alveolar cells.

Authors:  Naoki Ishiguro; Masanobu Oyabu; Toshihiro Sato; Tomoji Maeda; Hironobu Minami; Ikumi Tamai
Journal:  Pharm Res       Date:  2007-07-12       Impact factor: 4.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.